Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe
Rethinking neoadjuvant chemotherapy for breast cancer | The BMJ
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
Figure 1 from Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. | Semantic Scholar
Treatment of Metastatic Breast Cancer in Women Aged 65 Years and Older - Trevor Jolly, Grant R Williams, Ellen Jones, Hyman B Muss, 2012
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
Breast cancer recurrence: factors impacting occurrence and survival | Irish Journal of Medical Science (1971 -)
Update on systemic treatment for newly diagnosed inflammatory breast cancer - ScienceDirect
Endocrine Therapeutic Strategies for Patients with Hormone Receptor-positive Advanced Breast Cancer | touchONCOLOGY
The Evolving Role of Angiogenesis Inhibition in Treatment of Breast Cancer
Frontiers | Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study
Frontiers | Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative, Metastatic Breast Cancer
Real-world Treatment Patterns and Outcomes in HR+/HER2+ Metastatic Breast Cancer Patients: A National Cancer Database Analysis | Scientific Reports
Chemotherapy With Endocrine Therapy Shows Clinical Benefit With Improved Survival in Breast Cancer
Neoadjuvant Endocrine Therapy as an Alternative to Neoadjuvant Chemotherapy Among Hormone Receptor-Positive Breast Cancer Patients: Pathologic and Surgical Outcomes | Annals of Surgical Oncology
Chemotherapy Statistics | Success Rate & Cost
Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients - The Lancet Oncology
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Current Oncology | Free Full-Text | Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial - The Lancet Oncology
Abemaciclib plus aromatase inhibitor in advanced breast cancer
Efficacy and clinical outcome of chemotherapy and endocrine therapy as first-line treatment in patients with hormone receptor-positive HER2-negative metastatic breast cancer | Chinese Medical Journal
Adjuvant chemotherapy plus endocrine therapy fails to increase OS in breast cancer subset
Navigating HR+/HER2- Early Breast Cancer Treatment Strategies - Cancer Therapy Advisor
